Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $30959.0.

  • Abvc Biopharma's Interest Expenses fell 8595.51% to $30959.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $600054.0, marking a year-over-year increase of 1261.94%. This contributed to the annual value of $825899.0 for FY2024, which is 3713.05% down from last year.
  • Per Abvc Biopharma's latest filing, its Interest Expenses stood at $30959.0 for Q3 2025, which was down 8595.51% from $129413.0 recorded in Q2 2025.
  • Abvc Biopharma's Interest Expenses' 5-year high stood at $1.2 million during Q3 2023, with a 5-year trough of -$76368.0 in Q4 2023.
  • For the 5-year period, Abvc Biopharma's Interest Expenses averaged around $160215.1, with its median value being $126536.0 (2022).
  • Examining YoY changes over the last 5 years, Abvc Biopharma's Interest Expenses showed a top increase of 86306.51% in 2023 and a maximum decrease of 15679.57% in 2023.
  • Abvc Biopharma's Interest Expenses (Quarter) stood at -$24367.0 in 2021, then surged by 651.82% to $134461.0 in 2022, then plummeted by 156.8% to -$76368.0 in 2023, then soared by 383.78% to $216715.0 in 2024, then plummeted by 85.71% to $30959.0 in 2025.
  • Its Interest Expenses stands at $30959.0 for Q3 2025, versus $129413.0 for Q2 2025 and $222967.0 for Q1 2025.